347 related articles for article (PubMed ID: 26410190)
21. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.
Yang L; Liu Y; Li S; Zhao H; Lin Q; Yu H; Huang X; Zheng Q; Cheng T; Xia N
Vaccine; 2016 Nov; 34(48):5938-5945. PubMed ID: 27771182
[TBL] [Abstract][Full Text] [Related]
22. Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in
Yang Z; Gao F; Wang X; Shi L; Zhou Z; Jiang Y; Ma X; Zhang C; Zhou C; Zeng X; Liu G; Fan J; Mao Q; Shi L
Hum Vaccin Immunother; 2020 Jul; 16(7):1602-1610. PubMed ID: 31403352
[TBL] [Abstract][Full Text] [Related]
23. Efficient expression of enterovirus 71 based on virus-like particles vaccine.
Kim HJ; Son HS; Lee SW; Yoon Y; Hyeon JY; Chung GT; Lee JW; Yoo JS
PLoS One; 2019; 14(3):e0210477. PubMed ID: 30845175
[TBL] [Abstract][Full Text] [Related]
24. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease.
Tsou YL; Lin YW; Shao HY; Yu SL; Wu SR; Lin HY; Liu CC; Huang C; Chong P; Chow YH
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003692. PubMed ID: 25855976
[TBL] [Abstract][Full Text] [Related]
25. Characterization of human enterovirus71 virus-like particles used for vaccine antigens.
Zhao D; Sun B; Sun S; Fu B; Liu C; Liu D; Chu Y; Ma Y; Bai L; Wu Y; Zhou Y; Su W; Hou A; Cai L; Xu F; Kong W; Jiang C
PLoS One; 2017; 12(7):e0181182. PubMed ID: 28732070
[TBL] [Abstract][Full Text] [Related]
26. Immunological evaluation and comparison of different EV71 vaccine candidates.
Chou AH; Liu CC; Chang JY; Lien SP; Guo MS; Tasi HP; Hsiao KN; Liu SJ; Sia C; Wu SC; Lee MS; Hsiao CH; Wang JR; Chow YH; Chong P
Clin Dev Immunol; 2012; 2012():831282. PubMed ID: 23008736
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.
Lin CW; Liu CC; Lu TC; Liu SJ; Chow YH; Chong P; Huang MH
Biomed Res Int; 2014; 2014():670506. PubMed ID: 25006583
[TBL] [Abstract][Full Text] [Related]
28. Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.
Wang X; Ku Z; Zhang X; Ye X; Chen J; Liu Q; Zhang W; Zhang C; Fu Z; Jin X; Cong Y; Huang Z
J Virol; 2018 Jan; 92(1):. PubMed ID: 29070691
[TBL] [Abstract][Full Text] [Related]
29. Glycyrrhizic acid as the antiviral component of Glycyrrhiza uralensis Fisch. against coxsackievirus A16 and enterovirus 71 of hand foot and mouth disease.
Wang J; Chen X; Wang W; Zhang Y; Yang Z; Jin Y; Ge HM; Li E; Yang G
J Ethnopharmacol; 2013 May; 147(1):114-21. PubMed ID: 23454684
[TBL] [Abstract][Full Text] [Related]
30. Intradermal injection of a fractional dose of an inactivated HFMD vaccine elicits similar protective immunity to intramuscular inoculation of a full dose of an Al(OH)
Li M; Duan Y; Yang X; Yang Q; Pang B; Wang Y; Ren T; Wang X; Zhao Z; Liu S
Vaccine; 2017 Jun; 35(30):3709-3717. PubMed ID: 28576572
[TBL] [Abstract][Full Text] [Related]
31. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
[TBL] [Abstract][Full Text] [Related]
32. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield.
Chung CY; Chen CY; Lin SY; Chung YC; Chiu HY; Chi WK; Lin YL; Chiang BL; Chen WJ; Hu YC
Vaccine; 2010 Oct; 28(43):6951-7. PubMed ID: 20797455
[TBL] [Abstract][Full Text] [Related]
33. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.
Jiang L; Fan R; Sun S; Fan P; Su W; Zhou Y; Gao F; Xu F; Kong W; Jiang C
Vaccine; 2015 Nov; 33(48):6596-603. PubMed ID: 26529072
[TBL] [Abstract][Full Text] [Related]
34. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.
Liu CC; Chow YH; Chong P; Klein M
Vaccine; 2014 Oct; 32(47):6177-82. PubMed ID: 25218294
[TBL] [Abstract][Full Text] [Related]
35. Phage Display-Derived Cross-Reactive Neutralizing Antibody against Enterovirus 71 and Coxsackievirus A16.
Zhang X; Sun C; Xiao X; Pang L; Shen S; Zhang J; Cen S; Yang BB; Huang Y; Sheng W; Zeng Y
Jpn J Infect Dis; 2016; 69(1):66-74. PubMed ID: 26073737
[TBL] [Abstract][Full Text] [Related]
36. A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71.
Xu L; He D; Yang L; Li Z; Ye X; Yu H; Zhao H; Li S; Yuan L; Qian H; Que Y; Kuo Shih JW; Zhu H; Li Y; Cheng T; Xia N
Sci Rep; 2015 Aug; 5():12973. PubMed ID: 26243660
[TBL] [Abstract][Full Text] [Related]
37. Dynamic change of mother-source neutralizing antibodies against enterovirus 71 and coxsackievirus A16 in infants.
Mao QY; Liao XY; Yu X; Li N; Zhu FC; Zeng Y; Liang ZL; Li FX; Wang JZ; Lu FM; Zhuang H
Chin Med J (Engl); 2010 Jul; 123(13):1679-84. PubMed ID: 20819628
[TBL] [Abstract][Full Text] [Related]
38. EV71 vaccines: a first step towards multivalent hand, foot and mouth disease vaccines.
Klein MH
Expert Rev Vaccines; 2015 Mar; 14(3):337-40. PubMed ID: 25536888
[TBL] [Abstract][Full Text] [Related]
39. Production of EV71 vaccine candidates.
Chong P; Hsieh SY; Liu CC; Chou AH; Chang JY; Wu SC; Liu SJ; Chow YH; Su IJ; Klein M
Hum Vaccin Immunother; 2012 Dec; 8(12):1775-83. PubMed ID: 22992566
[TBL] [Abstract][Full Text] [Related]
40. Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses.
Zhao M; Bai Y; Liu W; Xiao X; Huang Y; Cen S; Chan PK; Sun X; Sheng W; Zeng Y
BMC Microbiol; 2013 Dec; 13():287. PubMed ID: 24320792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
